Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 25;21(7):2272.
doi: 10.3390/ijms21072272.

Could Intravenous Immunoglobulin Collected From Recovered Coronavirus Patients Protect Against COVID-19 and Strengthen the Immune System of New Patients?

Affiliations
Free PMC article

Could Intravenous Immunoglobulin Collected From Recovered Coronavirus Patients Protect Against COVID-19 and Strengthen the Immune System of New Patients?

Samir Jawhara. Int J Mol Sci. .
Free PMC article

Abstract

The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 °C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available.

Keywords: IVIg; coronavirus; immunotherapy; nCoV-2019; virus.

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Charlet R., Sendid B., Kaveri S.V., Poulain D., Bayry J., Jawhara S. Intravenous Immunoglobulin Therapy Eliminates Candida albicans and Maintains Intestinal Homeostasis in a Murine Model of Dextran Sulfate Sodium-Induced Colitis. Int. J. Mol. Sci. 2019;20 doi: 10.3390/ijms20061473. - DOI - PMC - PubMed
    1. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301. - DOI - PMC - PubMed
    1. Hu D., Zhu C., Ai L., He T., Wang Y., Ye F., Yang L., Ding C., Zhu X., Lv R., et al. Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg. Microbes Infect. 2018;7:154. doi: 10.1038/s41426-018-0155-5. - DOI - PMC - PubMed
    1. Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 2020 doi: 10.1016/S0140-6736(20)30154-9. - DOI - PMC - PubMed
    1. Liu P., Chen W., Chen J.P. Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica) Viruses. 2019;11 doi: 10.3390/v11110979. - DOI - PMC - PubMed

Substances

Supplementary concepts

Feedback